Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl-saline placebo Clear all
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Synera in Osteoarthritis Pain

NCT01654302
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Synera, Inactive patch
Drug
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 14, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

NCT03403751
View directory record Official record
Conditions
Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions
Reltecimod 0.5 mg/kg, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 14, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional

Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts

NCT01715012
View directory record Official record
Conditions
Third Degree Burns, Diabetes
Interventions
ST266, Saline
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 14, 2026, 4:58 PM EDT
Not listed Phase 4 Interventional

Early Caffeine in Preterm Neonates

NCT03086473
View directory record Official record
Conditions
BPD - Bronchopulmonary Dysplasia, Apnea of Prematurity, Hemodynamic Instability, Intubation
Interventions
Caffeine Citrate, Placebo (Normal Saline)
Drug
Lead sponsor
Jennifer Shepherd
Other
Eligibility
Up to 1 Day
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Increased Free Fatty Acids on Leptin Function

NCT01520454
View directory record Official record
Conditions
Obesity, Leptin Resistance
Interventions
Saline, Intralipid, Water, oral fat, Heparin
Drug · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 14, 2026, 4:58 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

NCT03505060
View directory record Official record
Conditions
HIV Infections
Interventions
DNA CON-S env, IHV01, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin Effects on Plantar Ulcer Recurrence

NCT00845897
View directory record Official record
Conditions
Diabetes Mellitus, Peripheral Neuropathy, Plantar Ulcers
Interventions
Botulinum Toxin, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 14, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Results available

Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain

NCT02044991
View directory record Official record
Conditions
Pelvic Girdle Pain
Interventions
Corticosteroid, Placebo Injection
Drug
Lead sponsor
Loyola University
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 14, 2026, 4:58 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Restylane Silk for Treatment of Chest Wrinkles

NCT03324997
View directory record Official record
Conditions
Wrinkle
Interventions
Restylane Silk, Saline, Optical Coherence Tomography
Drug · Device
Lead sponsor
Heidi Waldorf
Other
Eligibility
25 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot & Ankle Surgery

NCT01975285
View directory record Official record
Conditions
Foot and Ankle Procedures
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

NCT01990768
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 14, 2026, 4:58 PM EDT
Recruiting Phase 2 Interventional

IVIG for Infection Prevention After CAR-T-Cell Therapy

NCT05952804
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review
Biological · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

NCT04019444
View directory record Official record
Conditions
Rabies, Rabies Immunisation
Interventions
ChAd155-RG, Placebo, Rabies Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

NCT02611921
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

NCT03508947
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
WVE-210201, Placebo
Drug
Lead sponsor
Wave Life Sciences USA, Inc.
Industry
Eligibility
5 Years to 18 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

NCT02354859
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Gallium nitrate, Normal Saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

NCT02822599
View directory record Official record
Conditions
Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
Interventions
RiaStAP, Saline
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
1 Day to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 14, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

NCT04593784
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device)
Drug · Device
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

NCT02910635
View directory record Official record
Conditions
Abnormalities, Cardiovascular
Interventions
Volanesorsen, Moxifloxacin, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids

NCT01967433
View directory record Official record
Conditions
Colonoscopy, Adjunct Anesthesia Medication
Interventions
Diphenhydramine, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 14, 2026, 4:58 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT07266558
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, mRNA-1283, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
150
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 4:58 PM EDT